3B BlackBio Dx reports strong FY25 growth, declares dividend

3B BlackBio Dx Ltd. held its 53rd annual general meeting on September 26, 2025, revealing a strong financial performance for the year ended March 31, 2025. The company reported a consolidated revenue from operations of ₹96.47 million, profit before tax of ₹63.99 million, and profit after tax of ₹47.69 million, resulting in earnings per share of ₹55.66. Shareholders also approved a final dividend of ₹4.00 per equity share.

The company highlighted its strategic global expansion, with TRUPCR assays now present in over 70 countries. Export sales for FY25 surged to ₹171.04 million, a significant increase from ₹86.89 million in FY24, with a projected growth of 20-25% for international business in FY26. The UK subsidiary, TRUPCR Europe, also saw sales reach £1.28 million in FY25, up from £0.66 million in FY24, and anticipates continued strong growth of 20-25%.

Further strengthening its market position, 3B BlackBio Dx announced the acquisition of 100% stake in Coris Holding SRL, Belgium, for a total consideration of £2.765 million. This acquisition, completed on August 29, 2025, enhances the company's offerings in rapid diagnostic solutions and antibiotic resistance markers. Leadership changes included the re-appointment of Dhirendra Dubey as chairman-cum-managing director and the appointment of Vivek Saihgal as an independent director, alongside the appointment of Praveen Kumar Rai as secretarial auditor for five years.